IRON AND ALUMINUM INCREASE IN THE SUBSTANTIA-NIGRA OF PATIENTS WITH PARKINSONS-DISEASE - AN X-RAY-MICROANALYSIS

被引:457
作者
HIRSCH, EC [1 ]
BRANDEL, JP [1 ]
GALLE, P [1 ]
JAVOYAGID, F [1 ]
AGID, Y [1 ]
机构
[1] FAC MED CRETEIL, INSERM, SC 27, BIOPHYS LAB, F-94010 CRETEIL, FRANCE
关键词
IRON; ALUMINUM; PARKINSONS DISEASE; CELL DEATH; SUBSTANTIA NIGRA; NEUROMELANIN;
D O I
10.1111/j.1471-4159.1991.tb08170.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The levels of different elements were studied by x-ray microanalysis in the substantia nigra and the central gray substance of patients with Parkinson's disease, progressive supranuclear palsy, and matched controls. In control brains, only iron, potassium, silicium, sodium, sulfur, and zinc were within the limit of detection of the technique. The abundance of each element was different, but their respective concentrations in the two brain regions were similar, except for sulfur levels which were higher on neuromelanin aggregates in the substantia nigra than in nigral regions lacking neuromelanin, and in the central gray substance. In Parkinson's disease, but not in progressive supranuclear palsy, nigral iron levels increased in regions devoid of neuromelanin and decreased on neuromelanin aggregates, but were unchanged in the central gray substance, when compared to control values. Concentrations of the other elements in the central gray substance and substantia nigra were not different from controls in brains from patients with Parkinson's disease and progressive supranuclear palsy. Analysis of Lewy bodies in the parkinsonian substantia nigra revealed high levels of iron and the presence of aluminum. Metal abundance was not affected in progressive supranuclear palsy, in spite of the nigral cell death. This suggests that the increased iron levels and the detection of aluminum observed in Parkinson's disease are not solely the consequence of the neuronal degeneration.
引用
收藏
页码:446 / 451
页数:6
相关论文
共 33 条
[1]  
Agid Y, 1987, Adv Neurol, V45, P191
[2]  
ASENJO A, 1968, JOHNS HOPKINS MED J, V122, P284
[3]  
BARBEAU A, 1984, NEUROTOXICOLOGY, V5, P13
[4]   ALUMINUM, CHEMICAL PHYSIOLOGY, AND ALZHEIMERS-DISEASE [J].
BIRCHALL, JD ;
CHAPPELL, JS .
LANCET, 1988, 2 (8618) :1008-1010
[5]   INCORPORATION OF VARIOUS METAL IONS INTO IN VIVO- AND IN VITRO-PRODUCED MELANIN [J].
BRUENGER, FW ;
STOVER, BJ ;
ATHERTON, DR .
RADIATION RESEARCH, 1967, 32 (01) :1-&
[6]  
CANDY JM, 1986, LANCET, V1, P354
[7]   DECREASED FERRITIN LEVELS IN BRAIN IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
CARAYON, A ;
VIDAILHET, M ;
RUBERG, M ;
AGID, F ;
AGID, Y ;
LEES, AJ ;
WELLS, FR ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1990, 55 (01) :16-20
[8]   INCREASED NIGRAL IRON CONTENT AND ALTERATIONS IN OTHER METAL-IONS OCCURRING IN BRAIN IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
WELLS, FR ;
LEES, AJ ;
AGID, F ;
AGID, Y ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 52 (06) :1830-1836
[9]   BASAL LIPID-PEROXIDATION IN SUBSTANTIA NIGRA IS INCREASED IN PARKINSONS-DISEASE [J].
DEXTER, DT ;
CARTER, CJ ;
WELLS, FR ;
JAVOYAGID, F ;
AGID, Y ;
LEES, A ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 52 (02) :381-389
[10]  
DEXTER DT, 1989, BR J PHARM, V96